The DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
Breast-Cancer Stromal Cells with TP53 Mutations and Nodal Metastases
Open accessAbstract
BACKGROUND: The importance of cross-talk between a cancer and its microenvironment has been increasingly recognized. We hypothesized that mutational inactivation of the tumor-suppressor gene TP53 and genomic alterations in stromal cells of a tumor's microenvironment contribute to the clinical outcome. METHODS: We performed TP53 mutation analysis and genomewide analysis of loss of heterozygosity and allelic imbalance on DNA from isolated neoplastic epithelial and stromal cells from 43 patients with hereditary breast cancer and 175 patients with sporadic breast cancer. Compartment-specific patterns and TP53 mutations were analyzed. Associations between compartment-specific TP53 status, loss of heterozygosity or allelic imbalance, and clinical and pathological characteristics were computed. RESULTS: TP53 mutations were associated with an increased loss of heterozygosity and allelic imbalance in both hereditary and sporadic breast cancers, but samples from patients with hereditary disease had more frequent mutations than did those from patients with sporadic tumors (74.4% vs. 42.3%, P=0.001). Only 1 microsatellite locus (2p25.1) in stromal cells from hereditary breast cancers was associated with mutated TP53, whereas there were 66 such loci in cells from sporadic breast cancers. Somatic TP53 mutations in stroma, but not epithelium, of sporadic breast cancers were associated with regional nodal metastases (P=0.003). A specific set of five loci linked to an increased loss of heterozygosity and allelic imbalance in the stroma of sporadic tumors was associated with nodal metastases in the absence of TP53 mutations. No associations were found between any of the clinical or pathological features of hereditary breast cancer with somatic TP53 mutations. CONCLUSIONS: Stroma-specific loss of heterozygosity or allelic imbalance is associated with somatic TP53 mutations and regional lymph-node metastases in sporadic breast cancer but not in hereditary breast cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hapeman, D. E. (1991) · Technometrics · doi:10.1080/00401706.1991.10484817 · Cited by 9,373
p53 Mutations in Human Cancers
Hollstein, M., Sidransky, D., Vogelstein, B., & Harris, C. C. (1991) · Science · doi:10.1126/science.1905840 · Cited by 8,018
Cell-cycle checkpoints and cancer
Kastan, M. B., & Bartek, J. (2004) · Nature · doi:10.1038/nature03097 · Cited by 2,836
Wacholder, S., Chanock, S., Garcia-Closas, M., El ghormli, L., & Rothman, N. (2004) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djh075 · Cited by 1,754
p53 and Human Cancer: The First Ten Thousand Mutations
(1999) · Advances in Cancer Research · doi:10.1016/s0065-230x(08)60785-x · Cited by 986
BRCA1 and BRCA2: 1994 and beyond
Narod, S. A., & Foulkes, W. D. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1431 · Cited by 967
A comprehensive model for familial breast cancer incorporating BRCA1, BRCA2 and other genes
Antoniou, A. C., Pharoah, P. D. P., McMullan, G., Day, N. E., Stratton, M. R., Peto, J., Ponder, B. J., & Easton, D. F. (2002) · British Journal of Cancer · doi:10.1038/sj.bjc.6600008 · Cited by 495
The Influence of Extracellular Matrix on Gene Expression: Is Structure The Message?
Bissell, M. J., & Barcellos-Hoff, M. H. (1987) · Journal of Cell Science · doi:10.1242/jcs.1987.supplement_8.18 · Cited by 435
Kurose, K., Gilley, K., Matsumoto, S., Watson, P. H., Zhou, X.-P., & Eng, C. (2002) · Nature Genetics · doi:10.1038/ng1013 · Cited by 418
Self-citationMalignant transformation in a nontumorigenic human prostatic epithelial cell line.
Hayward, S. W., Wang, Y. Z., Cao, M., Hom, Y. K., Zhang, B., Grossfeld, G. D., Sudilovsky, D., & Cunha, G. R. (2001) · PubMed · Cited by 345
Fibrosis and cancer: Do myofibroblasts come also from epithelial cells via EMT?
Radisky, D. C., Kenny, P. A., & Bissell, M. J. (2007) · Journal of Cellular Biochemistry · doi:10.1002/jcb.21186 · Cited by 344
Widely dispersed p53 mutation in respiratory epithelium. A novel mechanism for field carcinogenesis.
Franklin, W. A., Gazdar, A. F., Haney, J., Wistuba, I. I., La Rosa, F. G., Kennedy, T., Ritchey, D. M., & Miller, Y. E. (1997) · Journal of Clinical Investigation · doi:10.1172/jci119748 · Cited by 330
Shekhar, M. P. V., Werdell, J., Santner, S. J., Pauley, R. J., & Tait, L. R. (2001) · PubMed · Cited by 327
Selective Evolution of Stromal Mesenchyme with p53 Loss in Response to Epithelial Tumorigenesis
Hill, R., Song, Y., Cardiff, R. D., & Van Dyke, T. (2005) · Cell · doi:10.1016/j.cell.2005.09.030 · Cited by 324
Somatic mutations in the p53 gene and prognosis in breast cancer: a meta-analysis
Pharoah, P. D. P., Day, N. E., & Caldas, C. (1999) · British Journal of Cancer · doi:10.1038/sj.bjc.6690628 · Cited by 308
Sneddon, J. B., Zhen, H. H., Montgomery, K., van de Rijn, M., Tward, A. D., West, R., Gladstone, H., Chang, H. Y., Morganroth, G. S., Oro, A. E., et al. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0606857103 · Cited by 299
BRCA1 induces DNA damage recognition factors and enhances nucleotide excision repair
Hartman, A.-R., & Ford, J. M. (2002) · Nature Genetics · doi:10.1038/ng953 · Cited by 233
Kurose, K. (2001) · Human Molecular Genetics · doi:10.1093/hmg/10.18.1907 · Cited by 191
The molecular pathology of hereditary breast cancer: genetic testing and therapeutic implications
Honrado, E., Benítez, J., & Palacios, J. (2005) · Modern Pathology · doi:10.1038/modpathol.3800453 · Cited by 190
Stromal Regulation of Neoplastic Development
Maffini, M. V., Calabro, J. M., Soto, A. M., & Sonnenschein, C. (2005) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)61227-8 · Cited by 160
Fukino, K., Shen, L., Matsumoto, S., Morris, Q., Mutter, G. L., & Eng, C. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-2866 · Cited by 141
Self-citationBarclay, W. W., Woodruff, R. D., Hall, M. C., & Cramer, S. D. (2004) · Endocrinology · doi:10.1210/en.2004-1123 · Cited by 121
Smith, P. D., Crossland, S., Parker, G. A., Osin, P., Brooks, L. A., Waller, J., Philp, E., Crompton, M. R., Gusterson, B. A., Allday, M. J., et al. (1999) · Oncogene · doi:10.1038/sj.onc.1202565 · Cited by 103
BRCA1 Is a Selective Co-activator of 14-3-3ς Gene Transcription in Mouse Embryonic Stem Cells
Aprelikova, O. N., Pace, A. J., Fang, B. S., Koller, B. H., & Liu, E. T. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.c100265200 · Cited by 99
Weber, F., Xu, Y., Zhang, L., Patócs, A., Shen, L., Platzer, P., & Eng, C. (2007) · JAMA · doi:10.1001/jama.297.2.187 · Cited by 97
Self-citationWeber, F., Shen, L., Fukino, K., Patócs, A., Mutter, G. L., Caldés, T., & Eng, C. (2006) · The American Journal of Human Genetics · doi:10.1086/504090 · Cited by 96
Self-citationOvergaard, J. (2000) · Acta Oncologica · doi:10.1080/028418600750013096 · Cited by 85
Ada-Nguema, A. S., Xenias, H. S., Sheetz, M. P., & Keely, P. J. (2006) · Journal of Cell Science · doi:10.1242/jcs.02835 · Cited by 82
Epithelial-stromal interactions and tumor progression: meeting summary and future directions.
Matrisian, L. M., Cunha, G. R., & Mohla, S. (2001) · PubMed · Cited by 80
P63 expression in normal, hyperplastic and malignant breast tissues
Wang, X., Mori, I., Tang, W., Nakamura, M., Nakamura, Y., Sato, M., Sakurai, T., & Kakudo, K. (2002) · Breast Cancer · doi:10.1007/bf02967592 · Cited by 78
TP53 mutations in familial breast cancer: Functional aspects
Gasco, M., Yuluğ, I. G., & Crook, T. (2003) · Human Mutation · doi:10.1002/humu.10173 · Cited by 71
Marsh, D. J., Zheng, Z., Zedenius, J., Kremer, H., Padberg, G. W. A. M., Larsson, C., Longy, M., & Eng, C. (1997) · PubMed · Cited by 69
Self-citationTP53 mutation, allelism and survival in non-small cell lung cancer
Nelson, H. H., Wilkojmen, M., Marsit, C. J., & Kelsey, K. T. (2005) · Carcinogenesis · doi:10.1093/carcin/bgi125 · Cited by 66
Patterns of Allelic Loss of Synchronous Adenocarcinomas of the Lung
Đačić, S., Ionescu, D. N., Finkelstein, S. D., & Yousem, S. A. (2005) · The American Journal of Surgical Pathology · doi:10.1097/01.pas.0000164367.96379.66 · Cited by 59
Martin, A.-M., Kanetsky, P. A., Amirimani, B., Colligon, T. A., Athanasiadis, G., Shih, H. A., Gerrero, M. R., Calzone, K., Rebbeck, T. R., & Weber, B. L. (2003) · Journal of Medical Genetics · doi:10.1136/jmg.40.4.e34 · Cited by 47
E2F6 negatively regulates ultraviolet-induced apoptosis via modulation of BRCA1
Ww, Y., Wang, Z.-H., Zhu, Y., & Yang, H.-T. (2006) · Cell Death and Differentiation · doi:10.1038/sj.cdd.4402062 · Cited by 43
Comprehensive mutational scanning of the p53 coding region by two- dimensional gene scanning
Rines, R. D. (1998) · Carcinogenesis · doi:10.1093/carcin/19.6.979 · Cited by 27
Hothorn, L. A. (2006) · Journal of Biopharmaceutical Statistics · doi:10.1080/10543400600860576 · Cited by 18
Cited by
Influence of tumour micro-environment heterogeneity on therapeutic response
Junttila, M. R., & de Sauvage, F. J. (2013) · Nature · doi:10.1038/nature12626 · Cited by 2,694
Turning foes to friends: targeting cancer-associated fibroblasts
Chen, X., & Song, E. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-018-0004-1 · Cited by 1,879
Mutant p53 in Cancer: New Functions and Therapeutic Opportunities
Muller, P. A. J., & Vousden, K. H. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.01.021 · Cited by 1,545
Diversity and biology of cancer-associated fibroblasts
Biffi, G., & Tuveson, D. A. (2021) · Physiological Reviews · doi:10.1152/physrev.00048.2019 · Cited by 1,265
Clinical and therapeutic relevance of cancer-associated fibroblasts
Chen, Y., McAndrews, K. M., & Kalluri, R. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00546-5 · Cited by 1,230
Metadata
- Authors
- Patocs, A., Zhang, L., Xu, Y., Weber, F., Caldes, T., Mutter, G. L., Platzer, P., & Eng, C.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2007-12-20
- Volume
- 357
- Issue
- 25
- Pages
- 2543-2551
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2058693971
- Cited by
- 297
- References
- 38
- FWCI
- 14.94
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.